Bill Commons

CO SB 66

died on adjournment

Regulation of Compounded Weight-Loss Medication

Colorado · 2026 Regular Session · upper

Follow this bill’s action updates (Atom)

Subscribe in a feed reader. The feed covers recorded actions from the last 30 days; Bill Commons may record an action after it happened at the legislature.

Quick answers

Did CO SB 66 pass?

No. CO SB 66 died when the 2026 Regular Session adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2026-01-28): Introduced In Senate - Assigned to Health & Human Services

What is CO SB 66 about?

The bill establishes regulations for the sale, transfer, or distribution of compounded weight-loss medication, which custom-made medications that, is defined in the bill as a drug that is:           Created by combining, mixing, or altering other drugs or drug substances;           Intended to be used by humans for obesity or weight management and contains an active ingredient that is named in a drug approved by the federal food and drug administration (FDA); and           A glucagon-like peptide-1 receptor agonist drug, known as a 'GLP-1' drug. Unlike mass-produced medications, a compound weight-loss medication is not subject to approval by the federal food and drug administration (FDA). A person may not sell, transfer, or distribute a compounded weight-loss medication unless the person confirms that the medication: FDA. Is made from bulk drug substances and drugs that are approved by the FDA when such approval is required; Was manufactured in compliance with FDA processes; Contains bulk drug substances that are pharmaceutical grade and are accompanied by a certificate of analysis containing information that is material to the safety and efficacy of the bulk drug substances; Was manufactured at a facility that is registered with the FDA and passed an FDA inspection within the previous 2 years; and Is verified for purity and accurate dosage.      Labels for compounded weight-loss medications must list all active and inactive ingredients, the quantity of those ingredients, and the ingredients' country of origin. There must also be a warning on the label stating that the compounded weight-loss medication has not been FDA-approved, has inadequate evidence of safety or efficacy, and has known and unknown side effects. A person must also provide certain disclosures to a patient when prescribing compounded weight-loss medications.      The bill prohibits the use of false or misleading claims, including unsubstantiated claims, when advertising or promoting compounded weight-loss medications.      A person that sells, transfers, or distributes compounded weight-lost medication must keep records related to the compounded weight-loss medication for at least 2 years after the date of expiration of the compounded weight-loss medication and make those records available for inspection by the state board of pharmacy.      The state board of pharmacy may issue fines of up to $1,000 per dose of compounded weight-loss medications that are sold or distributed in violation of the bill and may revoke a pharmacy or business license for violations.      The attorney general has authority to enforce this bill as a deceptive trade practice under the 'Colorado Consumer Protection Act'.      The bill establishes that a person engages in a deceptive trade practice when the person : Makes a false or misleading claim about a compounded weight-loss medication when advertising or promoting the medication; Distributes a compounded weight-loss medication when not legally authorized to distribute or transfer the drug used in the compounded weight-loss medication; Makes a materially false or misleading representation that the compounded weight-loss medication is approved by the FDA when the medication is not approved by the FDA; or Makes a materially false, misleading, or unverified claim regarding the efficacy, safety, performance, outcomes, or benefits of the compounded weight-loss medication.      The attorney general has exclusive authority to enforce the bill as a deceptive trade practice under the 'Colorado Consumer Protection Act'. There is no private right of action for a violation of the bill, and the provisions of the bill may only be enforced by the attorney general.     The bill does not apply to certain facilities or in certain circumstances, including: The administration of a compounded weight-loss medication by a practitioner at certain hospitals, clinics, and other health facilities licensed by the department of public health and environment; Long term care facilities; Assisted living residences; Home care agencies; The program of all-inclusive care for the elderly or PACE program; Adult day care facilities; or The compounding of drugs for animal use.(Note: Italicized words indicate new material added to the original summary; dashes through words indicate deletions from the original summary.)(Note: This summary applies to the reengrossed version of this bill as introduced in the second house.)

Who sponsors CO SB 66?

J. Jackson, I. Jodeh, J. Carson are the primary sponsors of CO SB 66.

Description

The bill establishes regulations for the sale, transfer, or distribution of compounded weight-loss medication, which custom-made medications that, is defined in the bill as a drug that is:           Created by combining, mixing, or altering other drugs or drug substances;           Intended to be used by humans for obesity or weight management and contains an active ingredient that is named in a drug approved by the federal food and drug administration (FDA); and           A glucagon-like peptide-1 receptor agonist drug, known as a 'GLP-1' drug. Unlike mass-produced medications, a compound weight-loss medication is not subject to approval by the federal food and drug administration (FDA). A person may not sell, transfer, or distribute a compounded weight-loss medication unless the person confirms that the medication: FDA. Is made from bulk drug substances and drugs that are approved by the FDA when such approval is required; Was manufactured in compliance with FDA processes; Contains bulk drug substances that are pharmaceutical grade and are accompanied by a certificate of analysis containing information that is material to the safety and efficacy of the bulk drug substances; Was manufactured at a facility that is registered with the FDA and passed an FDA inspection within the previous 2 years; and Is verified for purity and accurate dosage.      Labels for compounded weight-loss medications must list all active and inactive ingredients, the quantity of those ingredients, and the ingredients' country of origin. There must also be a warning on the label stating that the compounded weight-loss medication has not been FDA-approved, has inadequate evidence of safety or efficacy, and has known and unknown side effects. A person must also provide certain disclosures to a patient when prescribing compounded weight-loss medications.      The bill prohibits the use of false or misleading claims, including unsubstantiated claims, when advertising or promoting compounded weight-loss medications.      A person that sells, transfers, or distributes compounded weight-lost medication must keep records related to the compounded weight-loss medication for at least 2 years after the date of expiration of the compounded weight-loss medication and make those records available for inspection by the state board of pharmacy.      The state board of pharmacy may issue fines of up to $1,000 per dose of compounded weight-loss medications that are sold or distributed in violation of the bill and may revoke a pharmacy or business license for violations.      The attorney general has authority to enforce this bill as a deceptive trade practice under the 'Colorado Consumer Protection Act'.      The bill establishes that a person engages in a deceptive trade practice when the person : Makes a false or misleading claim about a compounded weight-loss medication when advertising or promoting the medication; Distributes a compounded weight-loss medication when not legally authorized to distribute or transfer the drug used in the compounded weight-loss medication; Makes a materially false or misleading representation that the compounded weight-loss medication is approved by the FDA when the medication is not approved by the FDA; or Makes a materially false, misleading, or unverified claim regarding the efficacy, safety, performance, outcomes, or benefits of the compounded weight-loss medication.      The attorney general has exclusive authority to enforce the bill as a deceptive trade practice under the 'Colorado Consumer Protection Act'. There is no private right of action for a violation of the bill, and the provisions of the bill may only be enforced by the attorney general.     The bill does not apply to certain facilities or in certain circumstances, including: The administration of a compounded weight-loss medication by a practitioner at certain hospitals, clinics, and other health facilities licensed by the department of public health and environment; Long term care facilities; Assisted living residences; Home care agencies; The program of all-inclusive care for the elderly or PACE program; Adult day care facilities; or The compounding of drugs for animal use.(Note: Italicized words indicate new material added to the original summary; dashes through words indicate deletions from the original summary.)(Note: This summary applies to the reengrossed version of this bill as introduced in the second house.)

Introduced
2026-01-28
Latest action
2026-01-28 — Introduced In Senate - Assigned to Health & Human Services
Bill type
bill
Last updated
—

Subjects

Sponsors

  • J. Jacksonsponsor
  • I. Jodehsponsor
  • J. Carsonsponsor

Committees

Not provided by source.

Action timeline

Newest first

  1. 2026-05-05

    House Committee on Health & Human Services Postpone Indefinitely

  2. 2026-04-20

    Introduced In House - Assigned to Health & Human Services

    introduction

  3. 2026-04-17

    Senate Third Reading Passed with Amendments - Floor

    passage,reading-3

  4. 2026-04-10

    Senate Third Reading Laid Over to 04/17/2026 - No Amendments

  5. 2026-04-09

    Senate Third Reading Laid Over to 04/10/2026 - No Amendments

  6. 2026-04-08

    Senate Third Reading Laid Over to 04/09/2026 - No Amendments

  7. 2026-04-07

    Senate Third Reading Laid Over to 04/08/2026 - No Amendments

  8. 2026-04-06

    Senate Third Reading Laid Over to 04/07/2026 - No Amendments

  9. 2026-03-30

    Senate Third Reading Laid Over to 04/06/2026 - No Amendments

  10. 2026-03-27

    Senate Third Reading Laid Over to 03/30/2026 - No Amendments

  11. 2026-03-26

    Senate Third Reading Laid Over to 03/27/2026 - No Amendments

  12. 2026-03-25

    Senate Third Reading Laid Over to 03/26/2026 - No Amendments

  13. 2026-03-24

    Senate Third Reading Laid Over to 03/25/2026 - No Amendments

  14. 2026-03-23

    Senate Third Reading Laid Over to 03/24/2026 - No Amendments

  15. 2026-03-20

    Senate Third Reading Laid Over to 03/23/2026 - No Amendments

  16. 2026-03-19

    Senate Third Reading Laid Over to 03/20/2026 - No Amendments

  17. 2026-03-18

    Senate Third Reading Laid Over to 03/19/2026 - No Amendments

  18. 2026-03-17

    Senate Third Reading Laid Over to 03/18/2026 - No Amendments

  19. 2026-03-16

    Senate Second Reading Passed with Amendments - Committee, Floor

    reading-2

  20. 2026-03-10

    Senate Second Reading Laid Over to 03/16/2026 - No Amendments

  21. 2026-03-05

    Senate Committee on Health & Human Services Refer Amended to Senate Committee of the Whole

    committee-passage,referral-committee

  22. 2026-01-28

    Introduced In Senate - Assigned to Health & Human Services

    introduction

Versions

Documents

Votes

  • Adopt amendment L.005 (Attachment J).

    2026-03-05 · pass · 0-0

  • Adopt amendment L.003 (Attachment I).

    2026-03-05 · pass · 0-0

  • Refer Senate Bill 26-066, as amended, to the Committee of the Whole.

    2026-03-05 · pass · 0-0

    Member-level votes (9)
    • Adrienne Benavidez: no
    • Scott Bright: no
    • John Carson: yes
    • Lisa Cutter: yes
    • Lindsey Daugherty: yes
    • Lisa Frizell: no
    • Iman Jodeh: yes
    • Mike Weissman: no
    • Kyle Mullica: yes
  • Postpone Senate Bill 26-066 indefinitely.

    2026-05-05 · pass · 0-0

    Member-level votes (13)
    • Regina English: excused
    • Lisa Feret: yes
    • Eliza Hamrick: yes
    • Dusty Johnson: yes
    • Karen McCormick: yes
    • Carlos Barron: yes
    • Mary Bradfield: yes
    • Brandi Bradley: yes
    • Gretchen Rydin: yes
    • Katie Stewart: yes
    • Dan Woog: yes
    • Sheila Lieder: yes
    • Lindsay Gilchrist: yes

Related bills

No related bills recorded for this bill.

Official source

Attribution

Data from openstates_api_sync, retrieved 2026-08-08T01:57:41.193191Z

Inspect retained evidence for changes recorded after evidence tracking began:

Session-wide evidence can include changes to other bills:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=CO&identifier=SB 66. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.